OKras identifies mutations in the KRAS gene in cancer cells using blood circulating tumor DNA (ctDNA). The prevalence of these mutations means that some cancer treatments may be ineffective and should be changed.

KRAS mutation

KRAS mutations are found in 15% to 20% of tumors, mostly leukemia, colorectal, pancreatic, and lung cancers. These mutations are reported in 30 % to 40 % of colorectal cancers and 15 % to 30 % of lung cancers. EGFR inhibitors are currently used to treat colorectal and non-small cell lung cancers. The KRAS mutation test is used to see if cancer cells are prone and respond to treatment. There are a few different tests to check for the KRAS mutations, mostly using tissues. OKras was developed to detect KRAS mutations in whole blood.